The examination of genetic background for CYP2C9*2 showed that the allele *2 frequency may discriminate MCS patients and SMCS patients from FM/CFS ones and that the frequency of genotype Ht*1/*2 differentiates MCS patients from controls. This evidence concerns the gene CYP2C9 and myalgic encephalomeyelitis/chronic fatigue syndrome.